[CIS PIDD] [cis-pidd] IGSC for autoimmune disorders

[CIS-PIDD]

Joe,
As noted, I have heard of a number of cases of high dose IGSC for
immunomodulation. You also use enzyme facilitated IGSC. Isabella Quinti has
a couple of cases, I think of ITP, in which she has used that approach. You
could give it every two weeks if you choose.
Richard Wasserman
Dallas

On Thu, Jun 16, 2016 at 3:08 AM, CIS-PIDD <cis-pidd at lists.clinimmsoc.org>
wrote:

> Hi Joe!
>
> The Oxford group, especially Siraj, may have one of the broadest
> experiences of immunomodulatory SCIG?
>
>
> http://www.ncbi.nlm.nih.gov/m/pubmed/?term=misbah+s+AND+subcutaneous+immunoglobulin+AND+
>
> It is used in neuropathies - especially in MMN - increasingly, and there
> is now a growing body of literature:
>
>
> http://www.ncbi.nlm.nih.gov/m/pubmed/27134672/?i=1&from=neuropathy%20AND%20subcutaneous%20immunoglobulin
>
> Hope this helps. It clearly works for most MMNs, thus if insurance issues,
> such literature helps at least in neuropathies when dealing with insurance
> companies?
>
> ATB
>
> Mikko
>
> Oyl Mikko Seppänen
> Harvinaissairauksien yksikkö (HAKE)
>
> Head, Rare Disease Center,
> Helsinki University Hospital (HUH)
> FINLAND
>
> phone +358 947180201
> GSM +358 50 4279606
> fax +358 9 47174703
>
> CIS-PIDD <cis-pidd at lists.clinimmsoc.org> kirjoitti 16.6.2016 kello 0.50:
>
> Colleagues:
>
>
>
> Has anyone used the subcutaneous route to administer ‘high dose’
> immunoglobulin (2g/kg) to patients with autoimmune disease?
>
>
>
> Joe Church
>
> Children’s Hospital Los Angeles
>
>
> ---------------------------------------------------------------------
> CONFIDENTIALITY NOTICE: This e-mail message, including any attachments,
> is for the sole use of the intended recipient(s) and may contain
> confidential
> or legally privileged information. Any unauthorized review, use, disclosure
> or distribution is prohibited. If you are not the intended recipient,
> please
> contact the sender by reply e-mail and destroy all copies of this original
> message.
>
> ---------------------------------------------------------------------
>
> ---
>
> You are currently subscribed to cis-pidd as: mikko.seppanen at hus.fi.
>
> To unsubscribe click here:
> http://cts.dundee.net/u?id=99266512.00d254228cd4b291924022bf56fac1f0&n=T&l=cis-pidd&o=3698364
>
> (It may be necessary to cut and paste the above URL if the line is broken)
>
> or send a blank email to
> leave-3698364-99266512.00d254228cd4b291924022bf56fac1f0 at lyris.dundee.net
>
> ---
>
> You are currently subscribed to cis-pidd as: drrichwasserman at gmail.com.
>
> To unsubscribe click here:
> http://cts.dundee.net/u?id=96396499.3449c9fd54f25f9fa0e022cb002b8c1e&n=T&l=cis-pidd&o=3698882
>
> (It may be necessary to cut and paste the above URL if the line is broken)
>
> or send a blank email to
> leave-3698882-96396499.3449c9fd54f25f9fa0e022cb002b8c1e at lyris.dundee.net
>



-- 
Richard L. Wasserman, MD, PhD
Allergy Partners of North Texas
7777 Forest Lane, Suite B-332
Dallas, Texas 75230
Office (972) 566-7788
Fax (972) 566-8837
Cell (214) 697-7211

---
You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://cts.dundee.net/u?id=96396833.5a9591ccd1e327fe6bc4d1543298c482&n=T&l=cis-pidd&o=3698899
or send a blank email to leave-3698899-96396833.5a9591ccd1e327fe6bc4d1543298c482 at lyris.dundee.net
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://pairlist7.pair.net/pipermail/pagid/attachments/20160616/bc425b94/attachment-0001.html>